FAMEFIX™ 200 DT

Quick Facts

Half Life 3–4 hours

Storage Store below 30°C, protect from light and moisture

Schedule H (Prescription required)

Onset of Action Peak plasma levels in 3–4 hours

Bioavailability ~40–50% (oral)

Route Oral (dispersible)

DPCO Yes — price regulated

Key Benefits

01

Patient-friendly dispersible formulation — dissolves completely in water for easy administration in children, elderly patients, and adults with dysphagia

02

Third-generation cephalosporin potency — superior gram-negative coverage compared to amoxycillin, including beta-lactamase-producing strains

03

DPCO-controlled pricing — maximum affordability for paediatric and general practice prescribers across all patient demographics

04

Once-daily dosing option — 400mg once daily improves adherence, especially important in paediatric outpatient management

05

Excellent tissue penetration — achieves therapeutic concentrations in middle ear fluid, sinus secretions, urinary tract, and respiratory mucosa

06

Multi-speciality utility — single formulation relevant across paediatrics, ENT, gynaecology, internal medicine, and general practice

Mechanism of Action

Cefixime is a third-generation oral cephalosporin that demonstrates potent bactericidal activity through inhibition of bacterial cell wall synthesis. It acts by binding with high affinity to penicillin-binding proteins (PBPs) — specifically PBP1 and PBP3 — located on the inner membrane of the bacterial cell wall. These proteins are essential enzymes responsible for catalysing the final cross-linking step of peptidoglycan biosynthesis. When cefixime occupies these binding sites, it prevents peptidoglycan cross-linking, causing the cell wall to weaken structurally. This results in osmotic instability, cell lysis, and bacterial death.

Cefixime demonstrates high intrinsic stability against many plasmid-mediated and chromosomally encoded beta-lactamase enzymes produced by gram-negative bacteria, including those produced by H. influenzae and M. catarrhalis. This stability, combined with its excellent oral bioavailability (approximately 40–50%) and once or twice-daily dosing, makes cefixime a first-choice oral cephalosporin in both adult and paediatric practice.

The dispersible tablet formulation dissolves rapidly in water, producing a uniform suspension that is easy to administer — particularly important in paediatric patients, the elderly, and adults with swallowing difficulties.

Indications

FAMEFIX™ 200 DT is indicated across a broad range of bacterial infections, with particular utility in paediatric, gynaecological, and ENT practice.

Paediatric Infections: Acute otitis media, pharyngitis, tonsillitis, and acute sinusitis in children above 6 months.

Urinary Tract Infections: Uncomplicated UTIs in children and adults caused by E. coli, Proteus mirabilis, and Klebsiella pneumoniae.

Gynaecological Infections: Uncomplicated gonorrhoea, cervicitis, and pelvic inflammatory disease as part of combination therapy.

Respiratory Tract Infections: Acute exacerbations of chronic bronchitis and community-acquired pneumonia involving H. influenzae or S. pneumoniae.

ENT Infections: Acute bacterial sinusitis, acute otitis media, and pharyngitis where cefixime's penetration into ENT tissues provides reliable clinical outcomes.

Enteric Fever: Typhoid and paratyphoid fever, where cefixime has demonstrated clinical efficacy particularly in paediatric populations.

Dosage & Administration

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.

Why FAMEFIX™ 200 DT?

Cefixime 200mg dispersible tablets occupy a critical position in both paediatric and adult outpatient antibiotic prescribing. Acute otitis media — one of the most common reasons for paediatric antibiotic prescriptions globally — is a primary indication where cefixime outperforms amoxycillin in cases involving beta-lactamase-producing organisms. FAMEFIX™ 200 DT's dispersible formulation makes it uniquely practical for this patient population.

For gynaecologists, cefixime remains a WHO-recommended agent for uncomplicated gonorrhoea. The DPCO regulation of this product ensures that despite the clinical premium of a third-generation cephalosporin, patients are not priced out of appropriate therapy. Seclis Labs' WHO-GMP manufacturing ensures that this affordability does not come at the cost of quality.